Cesare C. Berra

Milan, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 41 publications

Causes and consequences of discontinuation of GLP1RAs or tirzepatide.

Causes and consequences of discontinuation of GLP1RAs or tirzepatide.

Journal: Nature reviews. Endocrinology

Published: April 28, 2026

The use of semaglutide as an add-on therapy in patients with latent autoimmune diabetes in adults.

The use of semaglutide as an add-on therapy in patients with latent autoimmune diabetes in adults.

Journal: The Journal of clinical endocrinology and metabolism

Published: October 26, 2025

A glucose time in range of 70% attenuates the senescence-inducing and pro-inflammatory effects of hyperglycemia.

A glucose time in range of 70% attenuates the senescence-inducing and pro-inflammatory effects of hyperglycemia.

Journal: Cardiovascular diabetology

Published: August 24, 2025

Rethinking the Diabetes-Cardiovascular Disease Continuum: Toward Integrated Care.

Rethinking the Diabetes-Cardiovascular Disease Continuum: Toward Integrated Care.

Journal: Journal of clinical medicine

Published: August 24, 2025

The eternal struggle between titans: Fecal microbiota transplant (FMT) versus metformin in type 2 diabetes (T2D) gut dysmotility.

The eternal struggle between titans: Fecal microbiota transplant (FMT) versus metformin in type 2 diabetes (T2D) gut dysmotility.

Journal: Journal of advanced research

Published: May 08, 2025

Optimizing Body Composition During Weight Loss: The Role of Amino Acid Supplementation.

Optimizing Body Composition During Weight Loss: The Role of Amino Acid Supplementation.

Journal: Nutrients

Published: May 02, 2025

Sarcopenic obesity and weight loss-induced muscle mass loss.

Sarcopenic obesity and weight loss-induced muscle mass loss.

Journal: Current opinion in clinical nutrition and metabolic care

Published: April 29, 2025

PIONEER REAL Italy: Real-World Usage of Once-Daily Oral Semaglutide in Adults with Type 2 Diabetes.

PIONEER REAL Italy: Real-World Usage of Once-Daily Oral Semaglutide in Adults with Type 2 Diabetes.

Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders

Published: January 31, 2025

Reply to the letter comment of Su Boon Yong MD, PhD and colleagues to: Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE- 2 study.

Reply to the letter comment of Su Boon Yong MD, PhD and colleagues to: Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE- 2 study.

Journal: Pharmacological research

Published: January 30, 2025

Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE-2 study.

Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE-2 study.

Journal: Pharmacological research

Published: October 22, 2024

Body weight variability as a predictor of cardiovascular outcomes in type 1 diabetes: A nationwide cohort study.

Body weight variability as a predictor of cardiovascular outcomes in type 1 diabetes: A nationwide cohort study.

Journal: Diabetes, obesity & metabolism

Published: August 30, 2024

Inflammatory Trajectory of Type 2 Diabetes: Novel Opportunities for Early and Late Treatment.

Inflammatory Trajectory of Type 2 Diabetes: Novel Opportunities for Early and Late Treatment.

Journal: Cells

Published: August 29, 2024

Showing 1-12 of 41

Last Updated: 09/26/2026